AC
PTCT icon

Armistice Capital’s PTC Therapeutics PTCT Stock Holding History

Armistice Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.8M Buy
660,000
+270,000
+69% +$19.5M 0.66% 23
2026
Q1 		$26.6M Buy
+390,000
New +$27.6M 0.47% 37

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Armistice Capital's PTCT Position: Q2 2026 in Review

Armistice Capital reduced its PTC Therapeutics (PTCT) stake by 48% in Q2 2026, selling an estimated $72.4M and leaving 1,071,395 shares worth $87.4M. The position accounts for 1.07% of the portfolio, ranked #12.

Armistice Capital first reported a position in PTCT in Q4 2018 and has held it in 30 quarters since. The position peaked at $288M in Q4 2024. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Armistice Capital held 1,071,395 shares of PTC Therapeutics worth $87.4M as of Q2 2026.
  • Armistice Capital sold 1,003,054 PTC Therapeutics shares in Q2 2026, an estimated $72.4M.
  • PTC Therapeutics made up 1.07% of Armistice Capital's portfolio in Q2 2026, its #12 holding.
  • Armistice Capital first reported a position in PTC Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Armistice Capital's PTC Therapeutics position peaked at $288M in Q4 2024.
  • 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.